# Innovations in Biologicals: from Concept to Care

Alyce Maksoud Manufacturing Quality Branch Department of Health and Aged Care, TGA



## **GMP FORUM 2024**



tga.gov.au

## Agenda

- What is Bench to Bedside
- The bench to bedside Stages
- Introduction to Biologicals
- Priority Pathway
- GMP for IMPs
- Clinical Implementation
- Case Study
- Challenges and Solutions
- Future trends

### Bench to Bedside

#### Defining 'Bench to Bedside'


- Translating laboratory research into clinical treatments
- Importance in medical advancements

#### Why it's important

 A lot of great science ideas come from basic research, but without the collaboration of the industry, clinicians and a lot of luck, it is difficult to reach patients.



## The Bench to Bedside Process Stages



## **Basic Research**

#### Resourcing

#### • Description:

- Fundamental scientific discoveries
- Understanding disease mechanisms
- Examples:
  - Genetic studies
  - Cellular and molecular biology



## **Practical Research**

#### Resourcing




#### Description

- Testing in cell cultures and animal models
- Assessing safety and efficacy




#### Examples

- Biological assays
- Toxicology studies



#### **Clinical Trials**





#### Phases


Phase I: Safety and dosage Phase II: Efficacy and side effects Phase III: Confirmation and comparison Phase IV: Post-marketing surveillance



#### Importance

Ensuring that treatments are safe and effective

## **Regulatory Framework**



Home > About us > Legislation

#### Legislation and legislative instruments

📢 Listen 🔒 Print < Share

On this page	Legislation	
About legislation		
Acts and regulations	Legislation and legislative instruments 🗸 🗸	
Legislative amendments		
Legislative instruments	About the Australian therapeutic goods legislation	
Other legislative information	Declared goods orders	
e Therapeutic Goods Act, Regulations and Orders set out the requirements for inclusion of therapeutic ods in the Australian Register of Therapeutic Goods, including advertising, labelling, product appearance d appeal quidelines. Some provisions such as the scheduling of substances and the safe storage of	Excluded goods orders, determinations and specifications	

Australian legislation in full text is available from the Attorney General's Federal Register of Legislation 2.

therapeutic goods, are covered by the relevant State or Territory legislation.

egislation	
Legislation and legislative instruments	~
About the Australian therapeutic goods le	egislation
Declared goods orders	
Excluded goods orders, determinations ar specifications	nd
Instruments	
- Section 23 instruments	

#### **Key Legislation**

- Therapeutic Goods Act 1989 ullet
- Therapeutic Goods Regulations 1990 ullet(Schedule 16)

#### **Key Guidelines**

Good Clinical Practice (GCP)

## Clinical trials regulated by the TGA

Clinical trials with biologicals in Australia offer access to new (but unproven) therapies.

Each trial has a research purpose, and patients need to provide informed consent.



## Clinical trial regulation in Australia

Clinical trials with biologicals in Australia offer access to new (but unproven) therapies.

Each trial has a research purpose, and patients need to provide informed consent.



Notification under CTN Scheme or application under CTA Scheme required where investigational use of a product involves:

Any product not entered on the ARTG including:

- any new formulation of an existing product
- any new route of administration,
- In the case of an existing biologicals, new technology, new material or a new treatment modality

Use of product beyond the condition of its marketing approval, including:

- New indications extending the use of a medicine to a new population group
- Extension of doses or duration of treatments outside the approved range.

#### **Ethics Approval**

- Institutional Ethics Review Board (IERB)
- Required before TGA approval
- All trials must be notified to the TGA

Completion of online application Human Reseach Ethics Application (HREA) form

Review of submission checklist for HREC Payment of appropriate fees depending on type of application or amendment In case of multi-site submissions, determine if center is part of National Mutual Acceptance (NMA) scheme

## Submission and Review

- TGA Evaluation
  - Trial design, methodology, and safety data
- Investigator qualifications

#### Your Clinical Trial

#### Goal

- Propose a new technology to solve a health problem
- Present a mock design of the new technology and plans for a clinical trial to evaluate the technology

#### Must identify:

- A disease of global health significance
- Current medical technologies to treat the disease
- Limitations of those technologies in a resource challenged setting
- Design constraints of technologies in a resource challenged setting
- A new medical technology to treat the disease
- An appropriate clinical trial design
- Subjects to be tested
- Primary and Secondary outcomes
- Sample size

#### Must submit

- An illustrative prototype
- A clinical trial research protocol
- An informed consent document
- A presentation of your findings and proposed solution

## Reporting

- Adverse Events Reporting
- Immediate reporting of serious adverse events (SAEs)





Australian Government Department of Health and Aged Care Therapeutic Goods Administration

Login to TGA Business Services

Username or login ID		
Password		

Login

Forgotten your password?



#### **Post-trial obligations**

- Post-trial Reporting
  - Submission of results and data to the TGA





## Introduction to Biologicals

#### What are biologicals?

In Australia, 'biologicals' is the name for cell and tissue therapy products:

- Products in tissue banks
- Stem cell therapy product
- Excludes in vitro fertilisation products
- Excludes blood
- Other countries use different names for these products [advanced therapy medicinal products] (ATMP)

#### **Overview of ATMP**

ATMPs are medical products for human use and include:


- Gene Therapy medicinal product
- Somatic cell therapy products
- Tissue engineering products

Where a products contains human cells or tissues, the donation, procurement and testing of those tissues or cells required to comply with Therapeutic Goods Orders (TGOs) 108 and 109

## **Regulatory approval**

#### Process

- Submission of clinical trial data
- Review and approval





#### Australian Government

**Department of Health and Aged Care** Therapeutic Goods Administration





# Priority Review Pathway – key factors that influence the process

- Significant improvements in treatments
- Unmet medical need
- Innovative Technology
- Fast track designation
- Clinical evidence
- Public health impact
- Regulatory history




Better Evidence Better Health

# Manufacture in accordance with appropriate GMP

- All biologicals accessed through unapproved goods pathways, GMP applies
- unless there is an exemption in place unapproved biologicals used in first-inhuman clinical trials.


#### **Definition:**

 First-in-human: Innovative treatment or therapy, the trial testing a new drug, therapy or medical procedure that has never been used in humans before




#### GMP for IMPs: why?

- Protect study participants against risk that may arise from inadequate manufacturing, manipulation, storage and transport
- Make sure that results of clinical trials are not to be influenced by inadequate safety, insufficient quality or changed efficacy because of poor production



## Different chapters of GMP

- Quality Management
- Personnel
- Premises and equipment
- Documentation
- Production
- Quality control
- Contract manufacture and analysis
- Complaints and recalls
- Self-inspections



## **Quality Management Systems**

- Structured and organised approach
- Organisation quality policy
- QA appropriate for the manufacture of products
- Deviations
- Change management
- Risk management
- Self-inspections
- Management review
- Regular periodic review

#### Principles of Quality Management System



#### Infrastructure Overview


Facility Requirements:

Cleanrooms: standards (ISO 14644, Annex 1 PIC/s GMP and WHO)

- Controlled environments for cell culture and manipulation.
- Quality control laboratories

Technology


- Bioreactors for cell expansion
- Automation tools for processing
- Data management systems for compliance and traceability.



## Manufacturing process

#### Stages of production

- Cell Sourcing: Collection of cells (donor derived (autologous or allogeneic)
- Cell Expansion: Methods (for example: adherent vs. suspension cultures).
- Product formulation: Processes to ensure therapeutic efficacy.
- Quality control: testing for sterility or product microbial contamination testing, potency and viability.
- Regulatory compliance: Adhering to GMP and relevant regulations



## **Personnel Requirements**

Competent personnel

- Scientists and researcher for R&D
- Quality assurance and quality control specialists
- Manufacturing technicians

#### Training

• Continuous education on new technologies and regulatory requirements




### **Material Requirements**

**Raw Materials** 

- Cell lines, growth factors, culture media
- Ancillary materials: single use or multi-use materials, reagents, disposables and consumables

**Quality Assurance** 

- Sourcing from reputable and qualified suppliers
- Ensuring compliance with regulatory standards




#### Logistics Management

Supply Chain Management

- Procurement of raw materials and components
- Starting materials
- Inventory management to avoid shortages or excess.


Release for Supply and Distribution

- Cold chain logistics for temperature-sensitive products.
- Regulatory considerations for transportation of Biologicals




### Submission and Review

#### The process for inclusion of biologicals in the ARTG



## **Clinical implementation**

Ŷ	Steps	Integrating new treatments into clinical practice Training healthcare professionals
	Challenges	Cost Accessibility




## Case Study

#### Example

- A specific biological (ATMP) that successfully went from bench to bedside
- . Key milestones and outcomes






Source: Scienceofsingularity.com

#### **Challenges and Solutions**


	Challenges	Funding Time Regulatory hurdles
S	Solutions	Collaborative research Public-private partnership



## Future trends in biological manufacturing

-``@`-	Innovation	Advances in bioprocessing technologies
Ē,	Personalised medicine	Tailoring therapies to individual patient needs
	Sustainability	Eco-friendly practices in manufacturing processes

#### Conclusion



commercial sponsors

CBMP GTMP

## **Questions?**



Scan this QR code with your device to submit a question



## **GMP FORUM 2024**



#### Australian Government

**Department of Health and Aged Care** Therapeutic Goods Administration